Related Experiment Video
Updated: Jul 10, 2026
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
[Angiogenesis targeting in renal carcinomas]
Damien Pouessel1, Stephane Culine
1Département d'oncologie médicale, Centre régional de lutte contre le cancer Val d'Aurelle, Parc Euromédecine, 34298 Montpellier cedex 5.
Bulletin Du Cancer
|November 6, 2007
Summary
Sunitinib is a preferred first-line treatment for metastatic clear cell renal carcinoma over sorafenib, showing better response and progression-free survival. Both drugs target VEGF receptors but have different side effects and may exhibit cross-resistance.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Metastatic clear cell renal carcinoma (ccRCC) treatment is evolving.
- Angiogenesis inhibitors targeting VEGF receptors are key therapeutic agents.
Purpose of the Study:
- To compare the efficacy and toxicity of sunitinib and sorafenib in metastatic ccRCC.
- To evaluate their roles in first-line treatment strategies.
Main Methods:
- Review of available clinical data and trial results for sunitinib and sorafenib.
- Analysis of response rates and progression-free survival (PFS).
- Comparison of toxicity profiles.
Main Results:
- Sunitinib demonstrates superior efficacy compared to sorafenib in terms of response and PFS.
- Both agents are active in metastatic ccRCC, with immunotherapy reserved for specific cases.
- Distinct toxicity profiles necessitate individualized treatment selection.
Conclusions:
- Sunitinib is recommended as a first-line treatment for metastatic ccRCC.
- Individualized treatment selection based on toxicity profiles is crucial.
- Potential for partial cross-resistance between sunitinib and sorafenib warrants further investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:19Imaging Studies VII: Vascular Imaging
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...